Novo/Aradigm inhaled insulin to resume Phase III
This article was originally published in Pharmaceutical Approvals Monthly
Novo Nordisk and Aradigm will resume Phase III trials of their AERx inhaled insulin system in the second quarter, Novo says during its April 28 earnings call. The firms will study both type 1 and type 2 diabetes. In an interim analysis, the insulin Diabetes Management System had shown an unexpected delay in post-meal glucose suppression for type 1 diabetes, prompting Novo to caution that an indication may be limited to type 2. Lilly/Alkermes' AIR is expected to be the next inhaled insulin system to reach the market; Phase III trials in type 2 are underway. Pfizer's Exubera currently is the only inhaled insulin on the market...
You may also be interested in...
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.